Abstract

Introduction: Antipsychotic use in Long-Term Care (LTC) in Ontario, Canada continues to pose a challenge in the care of older adult patients living in these institutions. The dangers and patterns of inappropriate prescribing have been documented frequently. Most of the current literature focuses on dementia and behavioral and psychological symptoms of dementia, the role of prescribers, or on interprofessional interventions with person-centered care to address the behavior. Very little discussion has focused on the role of nurse practitioners and other frontline long-term care staff in the assessment and interactions with residents that may result in prescriptions of antipsychotics.
 Objectives: The purpose of this population based retrospective study of data from all LTC facilities in Ontario, Canada in 2019-2020 was to determine the extent to which antipsychotic medications were used in and the factors associated with this use. Reflections about the NP role are discussed.
 Results: The results demonstrate that over thirty percent of residents in LTC continue to receive antipsychotics and those with the responsive behaviours are significantly more likely to be prescribed antipsychotics. 
 Conclusions: The findings identify a potential link between over-burdened front-line staff and increased antipsychotic prescriptions, as well as continued use of antipsychotics in attempts to prevent harm to residents and staff at long-term care homes. Recommendations are made that include changes to legislation that will ensure optimal front-line care and time for care, increased training for front line staff and, in particular, how the role of the nurse practitioner in LTC can be utilized to optimize the appropriate use of antipsychotics, and the support of discontinuing or decreasing the dose of antipsychotics when required.

Highlights

  • Antipsychotic use in Long-Term Care (LTC) in Ontario, Canada continues to pose a challenge in the care of older adult patients living in these institutions

  • The care of residents in LTC has become a major focus in the past several years, including the time since COVID 19 has ravaged the older populations in developed countries (Ontario Ministry of Health and Long-Term Care, 2020 [MOHLTC])

  • In Canada risperidone is the only antipsychotic that is approved for the treatment of severe behavioral and psychological symptoms of dementia (BPSD) and the use of any of the other antipsychotics for BPSD, or for mood or behaviors that do not fall under the category of BPSD, would be off label use of the medication (Yunusa et al, 2019)

Read more

Summary

Introduction

Antipsychotic use in Long-Term Care (LTC) in Ontario, Canada continues to pose a challenge in the care of older adult patients living in these institutions. Very little discussion has focused on the role of nurse practitioners and other frontline long-term care staff in the assessment and interactions with residents that may result in prescriptions of antipsychotics. Antipsychotic medication is commonly prescribed to residents of long-term care (LTC) in Canada despite evidence demonstrating significant risk factors, including death (Alessi-Severini et al, 2013). Health Canada (2005) issued an advisory reinforcing that with the exception of short-term use of risperidone, antipsychotics for treatment of BPSD show an increase to all-cause mortality, and are not approved for use in this population. The rationale for avoiding the use of antipsychotics in older adults given in the Beers Criteria is the increased risk of stroke, decline in cognition and increased mortality (American Geriatrics Society, 2015)

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call